71 Results for "

IgG Fc region

" in MedChemExpress (MCE) Product Catalog:
Products (71)

71 Results for "IgG Fc region" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99033
CAS No.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816
Target:  

CD20 CD3

Research Areas:  

Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-NP006
CAS No.: 308083-69-4
Synonyms: SPA
Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99777
CAS No.: 2131089-46-6
Synonyms: TTI-621

Target:  

CD47

Research Areas:  

Cancer

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P72603
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Ig gamma-2A chain C region; Immunoglobulin heavy chain gamma polypeptide; Ighg
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70705
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FcGR3A; CD16; Prev. FcGR3; Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16); Prev. FcG3; Fc Of IgG Low Affinity IIIa Receptor Isoform 2; FcgammaRIIIa; Fc Of IgG Low Affinity IIIa Receptor Isoform 1; FcGRIIIA; Immunoglobulin G Fc Receptor III; CD16a; Neutrophil-Specific Antigen NA; Low Affinity Immunoglobulin Gamma Fc region Receptor III-A; Fc-Gamma Receptor IIIb (CD16); Fc Fragment Of IgG, Low Affinity IIIa, Receptor (CD16a); Fc Gamma Receptor III-A; Fc Fragment Of IgG Receptor IIIa; Fc-Gamma RIIIa; IgG Fc Receptor III-A; Fc-Gamma RIII; IgG Fc Receptor III-2; FcgammaRIIIA; Fc-Gamma RIII-Alpha; FcRIIIA; CD16a Antigen; FcRIIIa; CD16-II; FcR-10; IGFR3; FcRIII; CD16A; IMD20; Fc Gamma Receptor IIIa; Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment
Species:  
Human
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70771
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IGHG4; Immunoglobulin Heavy Constant Gamma 4; Immunoglobulin Heavy Constant Gamma 4 (G4m Marker); Ig Gamma-4 Chain C region; Immunoglobulin Heavy Chain Constant region Gamma 4
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P9954
CAS No.: 509077-98-9
Target:  

CD3

Research Areas:  

Cancer

Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
loading...
    loading...
Cat. No.: HY-P99674
CAS No.: 2364496-42-2
Synonyms: GEN-3009

Research Areas:  

Cancer

Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research .
loading...
    loading...
Cat. No.: HY-P99145A

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.
loading...
    loading...
Cat. No.: HY-E70884
Synonyms: EndoS2 D184M
Target:  

Glycosidase

Research Areas:  

Others

Endoglycosidase S2 (D184M mutant) (EndoS2 D184M) is a mutant endoglycosidase. Endoglycosidase S2 (D184M mutant) promotes the transfer of glyco-oxazoline donors with defined glycoforms to the Fc region of IgG antibodies .
loading...
    loading...
Cat. No.: HY-P990171

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.
loading...
    loading...
Cat. No.: HY-P990172

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.
loading...
    loading...
Cat. No.: HY-E70364
CAS No.: 1892548-76-3
Research Areas:  

Inflammation/Immunology

IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .
loading...
    loading...
Cat. No.: HY-P990707
CAS No.: 2631667-06-4
Synonyms: TTI-622; PF-07901801

Target:  

CD47

Research Areas:  

Inflammation/Immunology

Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
loading...
    loading...
Cat. No.: HY-P990941
CAS No.: 2853518-94-0
Synonyms: F131; GEN1184 antibody

Target:  

Antifolate

Research Areas:  

Inflammation/Immunology

Rinatabart (F131) is an IgG1-κ human antibody targeting FOLR1, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001). The Fc region of Rinatabart is engineered to reduce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. The KD values of Rinatabart binding to human FOLR1 in two sets of BLI assays are 1.528 nM and 5.296 nM, respectively. Rinatabart shows significantly lower affinity for FOLR2 and mouse FOLR1, and no reliable specific binding to FOLR3 and rat FOLR1. Rinatabart can be used in studies of FOLR1 targeting and antibody-drug conjugates .
loading...
    loading...
Cat. No.: HY-P990269

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.
loading...
    loading...